| P50 | author | Giulia Morace | Q56381016 |
| | Nicola Petrosillo | Q56395236 |
| | Antonino Giarratano | Q59668380 |
| | Elda Righi | Q79385925 |
| | Matteo Bassetti | Q88607142 |
| | Stefania Stefani | Q37838689 |
| | Massimo Antonelli | Q41654208 |
| P2093 | author name string | Gennaro De Pascale | |
| | Raffaele De Gaudio | |
| | Tereesita Mazzei | |
| P2860 | cites work | Anaerobic bacteria commonly colonize the lower airways of intubated ICU patients. | Q51664443 |
| | Survey of aspergillosis in non-neutropenic patients in Swiss teaching hospitals | Q51748116 |
| | The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis. | Q52896107 |
| | Galactomannan in Bronchoalveolar Lavage Fluid | Q57559940 |
| | Pharmacokinetics of Antifungal Agent Micafungin in Critically Ill Patients Receiving Continuous Hemodialysis Filtration | Q59153121 |
| | Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis | Q61758320 |
| | Post mortem examination in the intensive care unit: still useful? | Q64126970 |
| | Introduction to antifungal drugs | Q73688678 |
| | Comparison of premortem clinical diagnoses in critically iII patients and subsequent autopsy findings | Q73892686 |
| | Invasive pulmonary aspergillosis associated with high-dose inhaled fluticasone | Q74295643 |
| | Invasive aspergillosis | Q74492548 |
| | Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation | Q74579207 |
| | [Invasive pulmonary aspergillosis in the non-neutropenic critical patient: future challenges] | Q79385633 |
| | Diabetes induces rapid suppression of adaptive immunity followed by homeostatic T-cell proliferation | Q79525883 |
| | Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey | Q80052810 |
| | Invasive aspergillosis in critically ill patients without malignancy | Q80269940 |
| | Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit | Q80381584 |
| | Administration of voriconazole in patients with renal dysfunction | Q83301922 |
| | Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers | Q83556642 |
| | Pharmacokinetic evaluation of voriconazole treatment in critically ill patients undergoing continuous venovenous hemofiltration | Q84306172 |
| | Invasive pulmonary aspergillosis in intensive care units: is it a real problem? | Q84569579 |
| | Pharmacokinetics of anidulafungin in two critically ill patients with septic shock undergoing CVVH | Q86441854 |
| | Anidulafungin dosing in critically ill patients with continuous venovenous haemodiafiltration | Q87173846 |
| | Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome | Q24811601 |
| | Diagnostic accuracy of PCR alone compared to galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis: a systematic review | Q27013923 |
| | The role of combination antifungal therapy in the treatment of invasive aspergillosis: a systematic review | Q27021187 |
| | Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 |
| | Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America | Q28263689 |
| | Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome | Q28264458 |
| | Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial) | Q28298468 |
| | Invasive aspergillosis in the intensive care unit | Q28306909 |
| | Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen | Q33241227 |
| | Invasive pulmonary aspergillosis in patients with decompensated cirrhosis: case series | Q33271183 |
| | Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype | Q33608028 |
| | Rapid identification of Aspergillus fumigatus within the section Fumigati | Q33879030 |
| | Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system | Q33908389 |
| | Species identification of Aspergillus, Fusarium and Mucorales with direct surface analysis by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. | Q34007574 |
| | Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis | Q34045435 |
| | Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model | Q34251910 |
| | History of the development of azole derivatives | Q34293222 |
| | Aspergillus-PCR in bronchoalveolar lavage for detection of invasive pulmonary aspergillosis in immunocompromised patients | Q34432147 |
| | Overview of the lipid formulations of amphotericin B. | Q34501018 |
| | Evaluation of intravenous voriconazole in patients with compromised renal function | Q34548752 |
| | Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes | Q34559978 |
| | Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients | Q34630182 |
| | Evidence supporting a role for mammalian chitinases in efficacy of caspofungin against experimental aspergillosis in immunocompromised rats | Q35025196 |
| | Phase II dose escalation study of caspofungin for invasive Aspergillosis | Q35598439 |
| | Glucocorticoids and invasive fungal infections | Q35599856 |
| | Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1→3)-β-D-glucan assay, Candida score, and colonization index | Q35908296 |
| | Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients | Q36087577 |
| | Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring | Q36172497 |
| | Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens | Q36276870 |
| | Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. | Q36505462 |
| | Isolation of Aspergillus in critically ill patients: a potential marker of poor outcome | Q36686780 |
| | Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality | Q36715387 |
| | Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis | Q36757591 |
| | Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths | Q36785939 |
| | The safety of voriconazole | Q44200945 |
| | Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin | Q44304226 |
| | Amphotericin B deoxycholate administered by continuous infusion: does the dosage make a difference? | Q44396646 |
| | Factors associated with overall and attributable mortality in invasive aspergillosis | Q44431234 |
| | Acute invasive pulmonary aspergillosis in chronic lung disease--a review | Q44469494 |
| | Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies | Q44519647 |
| | Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients | Q44564506 |
| | The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial | Q44924916 |
| | Combination antifungal therapy for invasive aspergillosis | Q45096994 |
| | A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients | Q46059175 |
| | Impact of liposomal amphotericin B on renal function in critically ill patients with renal function impairment | Q46381018 |
| | Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes | Q46826187 |
| | Standard dosing regimen of liposomal amphotericin B is as effective as a high-loading dose for patients with invasive aspergillosis: AmBiLoad trial | Q46881807 |
| | Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study | Q46943408 |
| | Clinical features of invasive pulmonary aspergillosis vs. colonization in COPD patients distributed by gold stage. | Q46980161 |
| | Evaluation of the effect of obesity on voriconazole serum concentrations | Q47232083 |
| | A 7-year study of severe hospital-acquired pneumonia requiring ICU admission | Q47619717 |
| | ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. | Q47643534 |
| | Invasive aspergillosis in critically ill patients: analysis of risk factors for acquisition and mortality | Q49124894 |
| | Invasive pulmonary aspergillosis in non-neutropenic patients: analysis of a 14-month prospective clinical experience. | Q51000077 |
| | Non-decompensated cirrhosis as a risk factor for invasive aspergillosis: a case report and review of the immune dysfunction of cirrhosis | Q37009737 |
| | Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia. | Q37026715 |
| | Pharmacokinetics of caspofungin in critically ill patients on continuous renal replacement therapy. | Q37036404 |
| | Invasive pulmonary aspergillosis in patients with COPD: a report of five cases and systematic review of the literature | Q37095685 |
| | Relationship between trough plasma and epithelial lining fluid concentrations of voriconazole in lung transplant recipients. | Q37124182 |
| | Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/ | Q37164067 |
| | Voriconazole in the treatment of fungal eye infections: a review of current literature | Q37199485 |
| | Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach | Q37233354 |
| | Antifungal therapeutic drug monitoring: established and emerging indications | Q37310029 |
| | Pulmonary epithelial lining fluid concentrations after use of systemic amphotericin B lipid formulations. | Q37409856 |
| | Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults | Q37450705 |
| | Low but sufficient anidulafungin exposure in critically ill patients | Q37544395 |
| | Tissue penetration of antifungal agents. | Q37544911 |
| | In vitro susceptibility testing in Aspergillus species: an update | Q37742178 |
| | Fungal infections in ICU patients: epidemiology and the role of diagnostics | Q37811872 |
| | Echinocandin antifungal drugs in fungal infections: a comparison | Q37822777 |
| | Update on the optimal use of voriconazole for invasive fungal infections | Q37892901 |
| | ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients | Q37934487 |
| | The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012. | Q38025819 |
| | Voriconazole in clinical practice | Q38061736 |
| | Invasive aspergillosis in the intensive care unit | Q38066616 |
| | Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review | Q38073201 |
| | Azole resistance in Aspergillus fumigatus: a growing public health concern. | Q38152679 |
| | Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration | Q39169777 |
| | Invasive pulmonary aspergillosis in non-neutropenic patients with and without underlying disease: a single-centre retrospective analysis of 52 subjects | Q40271865 |
| | A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid | Q41907424 |
| | Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients | Q41998776 |
| | Effect of food on the pharmacokinetics of multiple‐dose oral voriconazole | Q42284203 |
| | NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis | Q42599568 |
| | Impact of the administration of liposomal amphotericin B in patients with renal function impairment at initiation of treatment | Q42946320 |
| | An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients | Q43258660 |
| | Chronic obstructive pulmonary disease patients with invasive pulmonary aspergillosis: benefits of intensive care? | Q43561043 |
| | Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study | Q43631437 |
| | Immunoparalysis as a cause for invasive aspergillosis? | Q43798573 |
| | Empirical antifungal therapy--new options, new tradeoffs | Q43864038 |
| | Outcomes of mechanically ventilated hematology patients with invasive pulmonary aspergillosis | Q43975147 |
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chronic obstructive pulmonary disease | Q199804 |
| | aspergillosis | Q259626 |
| | intensive care unit | Q5094647 |
| | hormone | Q11364 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 458 | |
| P577 | publication date | 2014-07-25 | |
| P1433 | published in | Critical Care | Q5186602 |
| P1476 | title | How to manage aspergillosis in non-neutropenic intensive care unit patients | |
| P478 | volume | 18 | |